Years of Life Lost in Incidental Prostate Cancer
The Prostate · 2026
DOI: 10.1002/pros.70222 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2026. Verfasst von Fabian Falkenbach und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Life Expectancy. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
It is unknown how survival is prematurely curtailed by incidental prostate cancer (IPCa). We aimed to quantify the average years of life lost (YLL) due to IPCa.
Methods
Within the SEER database 2004–2021, IPCa patients aged 45–75 were identified. Stratification was based on the Gleason sum, clinical stage, and active treatment (radical prostatectomy or radiotherapy) status. Monte Carlo simulated individual survival according to the Social Security Administration life tables. Subsequently, YLL was compared between IPCa patients versus controls using the Kaplan‐Meier method.
Results
Of 7324 IPCa patients, 1926 (26.7%) and 5398 (73.7%) received active treatment or no active treatment, respectively. Compared to population controls, IPCa patients exhibited a survival disadvantage of 0.23 YLL ( p < 0.001). Patients without active treatment exhibited a larger survival disadvantage of 0.25 YLL, compared to patients with active treatment (0.18 YLL). In subgroup analyses, the largest YLL disadvantage was observed in patients not receiving active treatment with Gleason sum 8–10 (2.67 YLL), clinical stage T1b (0.83 YLL), and both (Gleason sum 8–10, T1b: 3.02 YLL). Conversely, in active treatment patients with Gleason sum ≤ 7 and/or T1a, no YLL disadvantage was observed.
Conclusions
IPCa patients with advanced Gleason sum or clinical stage exhibited substantial YLL disadvantages, when they did not benefit from active treatment. Therefore, these patients should receive active treatment. Conversely, omitting active treatment in low‐risk IPCa patients did not impact premature death.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
- Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Urology, University Hospital Heidelberg, Heidelberg, Germany.
- Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
ORCID-Profile: Fabian Falkenbach, Calogero Catanzaro, Michele Nicolazzini, Jordan A Goyal
Zitieren
APA
Falkenbach, F., Longoni, M., Marmiroli, A., Chi Le, Q., Catanzaro, C., Nicolazzini, M., Polverino, F., Goyal, J. A., Schiavina, R., Volpe, A., Musi, G., Chun, F. K. H., Briganti, A., Montorsi, F., Saad, F., Shariat, S. F., Budäus, L., Graefen, M., & Karakiewicz, P. I. (2026). Years of Life Lost in Incidental Prostate Cancer. The Prostate. https://doi.org/10.1002/pros.70222
Vancouver
Falkenbach F, Longoni M, Marmiroli A, Chi Le Q, Catanzaro C, Nicolazzini M, et al. Years of Life Lost in Incidental Prostate Cancer. The Prostate. 2026. doi:10.1002/pros.70222
BibTeX
@article{Falkenbach2026,
author = {Falkenbach, Fabian and Longoni, Mattia and Marmiroli, Andrea and Chi Le, Quynh and Catanzaro, Calogero and Nicolazzini, Michele and Polverino, Federico and Goyal, Jordan A and Schiavina, Riccardo and Volpe, Alessandro and Musi, Gennaro and Chun, Felix K H and Briganti, Alberto and Montorsi, Francesco and Saad, Fred and Shariat, Shahrokh F and Budäus, Lars and Graefen, Markus and Karakiewicz, Pierre I},
title = {Years of Life Lost in Incidental Prostate Cancer},
journal = {The Prostate},
year = {2026},
doi = {10.1002/pros.70222}
}
EUVIMED